On May 21, 2026, Eli Lilly announced positive Phase 3 TRIUMPH-1 trial results for retatrutide, marking what may be the most significant development yet in the rapidly evolving field of obesity medicine. The announcement confirmed that retatrutide — a once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — delivered weight loss results described as more powerful than any currently approved obesity medication, including tirzepatide (Zepbound) and semaglutide (Wegovy). For the many patients who have been following this drug closely, and for the obesity medicine community at large, these data represent a potential turning point in how severe obesity is treated.
Retatrutide is commonly referred to as reta in patient communities, and interest has been building steadily since its Phase 2 results were published in the New England Journal of Medicine in 2023. What sets reta apart from earlier GLP-1 receptor agonists is its simultaneous activation of three distinct metabolic pathways — a design sometimes called "triple G" by those following the science closely — which appears to produce substantially greater fat mass reduction than dual or single agonists. The TRIUMPH-1 announcement has now given that early promise its most rigorous Phase 3 confirmation to date.
According to Eli Lilly's announcement on May 21, 2026, the TRIUMPH-1 Phase 3 trial demonstrated that retatrutide helped study participants lose approximately 70 pounds over 80 weeks, with average weight reductions reaching approximately 28% to 30% over the studied period. These figures align closely with — and in some analyses exceed — the 28.7% mean weight loss recorded at 68 weeks in the previously announced TRIUMPH-4 Phase 3 trial, which itself was already described as the highest mean weight loss ever recorded in a Phase 3 obesity clinical trial.
To put the TRIUMPH-1 results in context: losing 70 pounds on average means that a 250-pound individual could expect to reach approximately 180 pounds. For patients who have cycled through dietary interventions and earlier-generation medications without achieving durable results, this magnitude of weight loss has historically been associated only with bariatric surgery.
The TRIUMPH-4 data, already publicly available through an Eli Lilly press release from December 2025, used a carefully structured titration protocol: participants began at 2 mg weekly (weeks 1–4), escalated to 4 mg (weeks 5–8), then 6 mg (weeks 9–12), then 9 mg (weeks 13–16), before reaching the 12 mg maintenance dose at week 17 and beyond. This gradual dose escalation was designed to minimize gastrointestinal side effects — the most common adverse events in the GLP-1 drug class — while allowing the body to adapt to increasing receptor activation. Discontinuation rates in TRIUMPH-4 reached 18.2% at the 12 mg dose, compared to 4.0% in the placebo group, with some discontinuations attributed to what investigators described as perceived excessive weight loss — a finding without precedent in prior obesity drug trials.
Phase 2 data, published in the NEJM by Jastreboff et al. (2023), had already suggested that retatrutide's efficacy was dose-dependent and remarkable in scope. At 48 weeks, 100% of participants in the 8 mg arm achieved at least 5% weight loss, and up to 70% achieved 20% or greater weight loss. The Phase 3 TRIUMPH-1 results now extend those findings across a larger, more diverse population and a longer treatment duration.
The comparison to currently approved medications is instructive. Semaglutide (Wegovy), a GLP-1 receptor agonist, demonstrated a mean weight loss of approximately 14.9% at 68 weeks in the STEP-1 trial. Tirzepatide (Zepbound), a dual GLP-1/GIP agonist, achieved a mean weight loss of 20.9% at the 15 mg dose over 72 weeks in the SURMOUNT-1 trial. Retatrutide, as a triple agonist adding glucagon receptor activation to the GLP-1/GIP combination, appears to extend that trajectory meaningfully.
| Drug | Mechanism | Trial | Duration | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide (Zepbound) | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% (15 mg) |
| Retatrutide | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-4 (Phase 3) | 68 weeks | ~28.7% (12 mg) |
| Retatrutide | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-1 (Phase 3) | 80 weeks | ~28–30% (reported) |
Beyond weight loss percentages, the Phase 2 cardiometabolic data for retatrutide also deserve attention. At 24 weeks, participants in the higher-dose arms showed fasting triglyceride reductions of up to 39.3%, LDL cholesterol reductions of approximately 15–17%, and total cholesterol reductions approaching 17–18%. These lipid effects, driven in part by glucagon receptor activation's influence on hepatic fat metabolism, suggest that retatrutide may address obesity-related cardiovascular risk factors in ways that extend beyond weight loss alone. Whether the TRIUMPH-1 data confirm or expand these cardiometabolic findings will be an important focus when the peer-reviewed publication becomes available.
Patients who have experienced persistent food noise — the intrusive, constant mental preoccupation with food that is a hallmark of the neurobiological drivers of obesity — report that GLP-1-based medications can dramatically quiet this cognitive burden. The triple agonist mechanism of retatrutide, acting on appetite-regulating centers through multiple overlapping pathways, may produce even more pronounced suppression of food-seeking cognition, though head-to-head neurological data are not yet available.
As of April 2026, Eli Lilly had not yet filed a New Drug Application (NDA) for retatrutide with the FDA, and no confirmed approval timeline had been publicly announced. The positive TRIUMPH-1 results, combined with the previously reported TRIUMPH-4 data, now give Lilly a substantial Phase 3 efficacy and safety dataset to support a future regulatory submission. Peer-reviewed publication of the Phase 3 results, which remains pending, will be an important milestone for both the regulatory process and the clinical community's ability to fully evaluate the benefit-risk profile of the drug.
It is worth noting that TRIUMPH-4 data identified dysesthesia — an abnormal or unpleasant skin sensation — in 20.9% of participants at the 12 mg dose, compared to 0.7% in the placebo group. Phase 2 data similarly flagged hyperesthesia and dysesthesia as dose-dependent findings, occurring in approximately 12.9–14.3% of participants at higher doses. This adverse event profile will likely be a key area of regulatory scrutiny and will inform prescribing guidance if and when the drug receives approval.
For patients currently managing obesity with or without comorbidities such as hypertension or dyslipidemia, the trajectory of the retatrutide program is worth following closely. The TRIUMPH-1 announcement represents a meaningful step toward what could become a new standard of care in obesity pharmacotherapy — one that, for the first time, approaches surgical-level weight loss outcomes through a subcutaneous injection.
Stay informed as the retatrutide story develops. The waitlist at glp3md.com is designed to keep prospective patients informed about retatrutide's clinical progress, regulatory milestones, and availability updates as they occur. Joining the waitlist does not constitute enrollment in a clinical trial, and no promises are made regarding access to medication or treatment — retatrutide is not currently FDA-approved and is not available for prescription use. However, for patients who want to be positioned with current, clinically accurate information when the landscape changes, the glp3md waitlist is the place to start. Join the waitlist at glp3md.com today.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.